Please assess the completion status of the following clinical trial:

Trial Title: TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C levels \>2.5 mmol/L and \<4.5 mmol/L, HDL-C levels \<1.8 mmol/L and \>0.8 mmol/L, and TG levels \<4.5 mmol/L after run in or washout of existing therapies~* Not on lipid-altering therapy at screening or on lipid-altering treatment regimens at screening~Exclusion Criteria:~* Body mass index \>32 kg/m2;~* Participation in another clinical study involving an investigational or marketed drug within 30 days prior to enrolment (Visit 2);~* Any clinical manifestation of atherosclerotic vascular disease;~* Diagnosis of type 1 diabetes;~* Uncontrolled type 2 diabetes: haemoglobin A1c \>8%;~* Uncontrolled hypertension: sitting systolic blood pressure \>160 mmHg and/or sitting diastolic blood pressure \>90 mmHg;~* History of hyperaldosteronism;~* Active muscle disease or persistent creatine kinase concentration \>3 × the upper limit of normal (ULN). One retest will be allowed after 1 week to verify the result;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: PLACEBO_COMPARATOR): TA-8995 0mg (placebo) \& placebo statin
- Group 2 (Type: EXPERIMENTAL): TA-8995 1mg \& placebo statin
- Group 3 (Type: EXPERIMENTAL): TA-8995 2.5mg \& placebo statin
- Group 4 (Type: EXPERIMENTAL): TA-8995 5mg \& placebo statin
- Group 5 (Type: EXPERIMENTAL): TA-8995 10mg \& placebo statin
- Group 6 (Type: ACTIVE_COMPARATOR): TA-8995 0mg (placebo) \& atorvastatin 20mg
- Group 7 (Type: ACTIVE_COMPARATOR): TA-8995 10mg \& atorvastatin 20mg
- Group 8 (Type: ACTIVE_COMPARATOR): TA-8995 0mg (placebo) \& rosuvastatin 10mg
- Group 9 (Type: ACTIVE_COMPARATOR): TA-8995 10mg \& rosuvastatin 10mg

Based on this trial design, predict the completion outcome and termination type (if applicable).